Results 1 to 10 of about 5,781 (240)

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies [PDF]

EJNMMI Research, 2015
Background: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also referred to as peptide receptor ...
Sander Bison, Joost Haeck, Karin Bol, Stuart Koelewijn, Harald C. Groen, Marleen Melis, Jifke F. Veenland, Monique R. Bernsen, Marion de Jong   +8 more
core   +7 more sources

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. [PDF]

J Clin Med, 2021
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE.
Camus B, Cottereau AS, Palmieri LJ, Dermine S, Tenenbaum F, Brezault C, Coriat R.   +6 more
europepmc   +6 more sources

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements. [PDF]

Cancers (Basel), 2023
Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has
Merola E, Grana CM.
europepmc   +6 more sources

Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. [PDF]

Cancers (Basel), 2021
Dosimetry during peptide receptor radionuclide therapy (PRRT) has mainly focused on normal organs and less on the tumors. The absorbed dose in one target tumor per patient and several response related factors were assessed in 23 pancreatic neuroendocrine neoplasms (P-NENs) and 25 small-intestinal NEN (SI-NENs) during PRRT with 177Lu-DOTATATE. The total
Jahn U, Ilan E, Sandström M, Lubberink M, Garske-Román U, Sundin A.   +5 more
europepmc   +4 more sources

Survival predictors of ¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). [PDF]

J Cancer Res Clin Oncol, 2022
Abstract Purpose 177Lu-Dotatate is an emerging treatment modality for patients with unresectable or metastatic well-differentiated NETs. This study examines survival predictors in patients who received 177Lu-Dotatate.
Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT.   +9 more
europepmc   +5 more sources

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer [PDF]

Case Reports in Oncology, 2019
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies.
Pashtoon M. Kasi, Akash Sharma, Manoj K. Jain   +2 more
doaj   +2 more sources

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression. [PDF]

EJNMMI Res, 2023
Jahn U, Garske-Román U, Sandström M, Lubberink M, Sundin A.   +4 more
europepmc   +5 more sources

A case report of enduring benefit of sequential PRRT in malignant insulinoma [PDF]

EJNMMI Reports
We report the case of a 62-year-old woman diagnosed in 2015 with de novo metastatic malignant insulinoma. She presented severe hypoglycemia and was initially treated with somatostatin analogs, chemotherapy (capecitabine-temozolomide), and diazoxide, but ...
Cristina-An Wang Zhang, Natacha Driessens, Magdalena Mileva, Amélie Deleporte, Patrick Flamen, Ioannis Karfis   +5 more
doaj   +2 more sources

Correction: Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
,
europepmc   +3 more sources

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
Ataei-Nakhaei S, Aryana K, Mostafavi SM, Kosari HM, Esmatinia M, Aghaee A.   +5 more
europepmc   +3 more sources